BioLineRx Ltd.
(NASDAQ : BLRX)

( )
BLRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. 0.13%365.731.1%$1198.66m
JNJJohnson & Johnson 0.02%177.270.7%$1105.44m
MRKMerck & Co., Inc. 0.87%108.430.7%$979.75m
PFEPfizer Inc. 0.78%49.600.9%$971.15m
ABBVAbbVie, Inc. -0.80%158.341.9%$838.84m
BMYBristol-Myers Squibb Co. -0.13%79.141.1%$734.71m
AZNAstraZeneca Plc 0.06%66.211.0%$359.51m
IDXXIDEXX Laboratories, Inc. -2.74%400.103.9%$216.62m
CTLTCatalent, Inc. 13.32%46.911.9%$200.95m
GSKGSK Plc -0.65%33.770.3%$199.83m
HZNPHorizon Therapeutics Plc -0.36%78.005.4%$196.93m
NVSNovartis AG -0.04%87.680.2%$186.54m
NVONovo Nordisk A/S 2.08%121.270.1%$162.88m
ALNYAlnylam Pharmaceuticals, Inc. -1.66%209.208.0%$139.45m
VTRSViatris, Inc. -0.72%11.060.0%$119.33m

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.